William V. Bobo, M.D., M.P.H.

The purpose of this study is to validate measures of depression, anxiety, traumatic stress, and factors related to these outcomes in medical patients, to develop a model for identifying persons with myocarditis who are at risk for depressive and anxiety disorders (clinically significant depressive and anxious symptoms), and for examining the effects of anxiety and depression on quality of life and health outcomes in respondents with myocarditis and caregivers.

The primary study objective is to develop a longitudinal multi-omic and digitomic dataset suitable for the identification of novel biological and physiological markers of transitions between depressive states (categorically defined) and depressive symptoms (as a continuous measure).

Study hypothesis: Do serial low-dose ketamine infusions, followed by weekly maintenance infusions, increase the length of time depressive symptoms stay in remission and the length of time associated suicide risk is improved? Brief Summary: This open label clinical trial is intended to further clarify initial response to low-dose ketamine infusion with repeated dosing and maintenance treatment model. Primary outcomes will be reduction in depression severity and reduction of suicide risk along with duration of response.

The primary purpose of this study is to evaluate the degree of statistical agreement between observed clinical outcomes (non-response/remission) after 8 weeks of treatment and the outcomes predicted by an Augmented Human Intelligence (AHI)-based clinical decision support tool after 2 weeks of follow up.

This study will evaluate the safety and effectiveness of deep brain stimulation in treating people with severe and otherwise treatment-resistant obsessive-compulsive disorder.

The purpose of this study is to validate measures of depression, anxiety, traumatic stress, and factors related to these outcomes in medical patients, to develop a model for identifying persons with myocarditis who are at risk for depressive and anxiety disorders (clinically significant depressive and anxious symptoms), and for examining the effects of anxiety and depression on quality of life and health outcomes in respondents with myocarditis and caregivers.

The purpose of this study is to evaluate the feasibility of developing a microbiome probe of depression and to evaluate the microbiome change in a preliminary analysis of treatment response (n=20) vs. non response (n=20) to the antidepressant citalopram. This study is a 12 week open trial that will enroll approximately 80 participants (anticipated 40 study completers with paired biomarker data) with an episode of major depression, Bipolar I or Bipolar II and 40 age- and sex-matched healthy controls.

This research project’s vision is to develop a technology to predict burnout in RNs by combining workplace, psychological, and physiological factors, and exploring the barriers to adopting such a technology.

Aim 1 is to create a unique, open-access, de-identified dataset that transforms the science of burnout internationally and informs the interaction of continuous physiological measures (measured from smart watches) and repeated psychological and work-related factors for predicting burnout in RNs at Mayo Clinic’s Florida and Rochester sites.

Aim 2 is to develop an analytical framework combining probabilistic graphical models (PGMs) and multitask learning (MTL) to derive interpretable predictions of burnout using the data gathered in Aim 1. 

Finally, two supplemental analytical aims of this project are to examine burnout impact on absenteeism and related costs for RNs, and to assess the impact of burnout on nursing-sensitive outcomes.